The global bio-preservation market is projected to grow from USD 4.52 billion in 2025 to USD 44.45 billion by 2035 at a CAGR of 25.68%, driven by cell and gene therapy commercialization, cold chain expansion, and iPSC applications. North America commands 46% market share, with media consumables achieving 32% CAGR. Record FDA approvals (8 in 2024) and 23 anticipated filings in 2025 are accelerating commercial cold chain requirements.

The biopreservation market is experiencing significant growth driven by healthcare expenditure, research investment, and regenerative medicine, with North America leading and Asia Pacific showing fastest potential expansion. Key challenges include storage logistics and sample transportation standards.

The global biobanking market is projected to reach a valuation of USD 95.5 billion by 2031, growing at a CAGR of 6.8% during the forecast period. The growth is driven by the rising demand for personalized medicine, improvements in genomic research, and the high incidence of chronic illnesses worldwide.

The global biobanking market is expected to grow from $72 billion in 2023 to $95.5 billion by 2031, driven by rising demand for personalized medicine, improvements in genomic research, and the high incidence of chronic diseases. The disease-based biobanks and population-based biobanks segments are expected to lead the market.

The antibody production market is expected to grow significantly due to the increasing demand for targeted therapies and advancements in biotechnology, such as recombinant DNA technology and high-throughput screening methods.

Hyperfine's Swoop system has shown promising results in a study on its ability to quickly assess stroke patients and guide treatment decisions. The study, part of the larger ACTION PMR study, found the Swoop system to be a reliable tool for enabling critical stroke treatment choices in urgent care settings.

Throughout the last three months, 5 analysts have evaluated Azenta (NASDAQ:AZTA), offering a diverse set of opinions from bullish to bearish. The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 0 3 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 1 0 0 0 0 3M Ago 1 0 2 0 0 In the assessment of 12-month price targets, analysts unveil insights for Azenta, presenting an average target of $64.2, a high estimate of $75.00, and a low estimate of $53.00. A decline of 3.46% from the prior average price target is evident in the current average. Analyzing Analyst Ratings: A Detailed Breakdown A comprehensive examination of how financial experts perceive Azenta is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Vijay Kumar Evercore ISI Group Raises In-Line $53.00 $52.00 David Saxon Needham Lowers Buy $69.00 $75.00 David Saxon Needham Maintains Buy $75.00 $75.00 Vijay Kumar Evercore ISI Group Lowers In-Line $60.00 $64.00 Matthew Stanton Jefferies Announces Hold $64.00 - Key Insights: Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their ...Full story available on Benzinga.com

Across the recent three months, 7 analysts have shared their insights on Azenta (NASDAQ:AZTA), expressing a variety of opinions spanning from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 0 2 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 3 0 2 0 0 3M Ago 1 0 0 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $70.43, along with a high estimate of $75.00 and a low estimate of $60.00. Experiencing a 2.52% decline, the current average is now lower than the previous average price target of $72.25. Investigating Analyst Ratings: An Elaborate Study A comprehensive examination of how financial experts perceive Azenta is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target David Saxon Needham Lowers Buy $69.00 $75.00 David Saxon Needham Maintains Buy $75.00 $75.00 Vijay Kumar Evercore ISI Group Lowers In-Line $60.00 $64.00 Matthew Stanton Jefferies Announces Hold $64.00 - David Saxon Needham Maintains Buy $75.00 - David Saxon Needham Maintains Buy $75.00 $75.00 David Saxon Needham Maintains Buy $75.00 - Key Insights: Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments ...Full story available on Benzinga.com

Fulgent Genetics (FLGT) delivered earnings and revenue surprises of 96.97% and 1.90%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

During the last three months, 7 analysts shared their evaluations of Azenta (NASDAQ:AZTA), revealing diverse outlooks from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 6 0 1 0 0 Last 30D 1 0 0 0 0 1M Ago 2 0 0 0 0 2M Ago 2 0 1 0 0 3M Ago 1 0 0 0 0 Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $75.0, a high estimate of $79.00, and a low estimate of $70.00. Surpassing the previous average price target of $70.00, the current average has increased by 7.14%. Understanding Analyst Ratings: A Comprehensive Breakdown The analysis of recent analyst actions sheds light on the perception of Azenta by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target David Saxon Needham Maintains Buy $75.00 - David Saxon Needham Maintains Buy $75.00 $75.00 David Saxon Needham Maintains Buy $75.00 - Jacob Johnson Stephens & Co. Maintains Equal-Weight $70.00 - David Saxon Needham Lowers Buy $75.00 $76.00 Yuan Zhi B. Riley Securities Raises Buy $79.00 $61.00 David Saxon Needham Raises Buy $76.00 $68.00 Key Insights: Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction ...Full story available on Benzinga.com

In the preceding three months, 5 analysts have released ratings for Azenta (NASDAQ:AZTA), presenting a wide array of perspectives from bullish to bearish. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 0 1 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 1 0 0 2M Ago 2 0 0 0 0 3M Ago 0 0 0 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $75.0, a high estimate of $79.00, and a low estimate of $70.00. This current average reflects an increase of 9.76% from the previous average price target of $68.33. Interpreting Analyst Ratings: A Closer Look The perception of Azenta by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target David Saxon Needham Maintains Buy $75.00 - Jacob Johnson Stephens & Co. Maintains Equal-Weight $70.00 - David Saxon Needham Lowers Buy $75.00 $76.00 Yuan Zhi B. Riley Securities Raises Buy $79.00 $61.00 David Saxon Needham Raises Buy $76.00 $68.00 Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Azenta. This information provides a ...Full story available on Benzinga.com

Inspire (INSP) delivered earnings and revenue surprises of 1,325% and 0.05%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?